Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2013-02-28
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the
growth of cancer cells by stopping them from dividing or killing them. An autologous stem
cell transplant may be able to replace the blood-forming cells that were destroyed by the
chemotherapy.
PURPOSE: This phase II trial is studying how well giving busulfan together with
cyclophosphamide followed by an autologous stem cell transplant works in treating patients
with multiple myeloma.